GlassScriptPhysician profile
Camille A Muller
NPI 1790230613
$11,352.85
in general payments reported to CMS, 2019-2025
23 companies · $3,140 in 2025
The $3,140 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $2,661 · 2023: $2,462 · 2024: $2,419 · 2025: $3,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,021.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,923.02 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,538.89 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,509.72 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,499.10 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,395.55 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $971.37 | 2022-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $856.46 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $329.77 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $303.23 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $236.79 | 2021-2025 | Fanapt |
| Axsome Therapeutics, INC. | $139.82 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $129.23 | 2022-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $127.27 | 2024-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $111.32 | 2021-2022 | |
| Corium, LLC | $46.28 | 2022-2025 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tms Neurohealth Centers INC. | $43.66 | 2025 | Tms Neurohealth Centers INC. |
| Takeda Pharmaceuticals U.S.A., INC. | $39.19 | 2021 | |
| Collegium Pharmaceutical, INC. | $33.97 | 2025 | Jornay Pm |
| Biogen, INC. | $28.07 | 2024 | |
| Ironshore Pharmaceuticals INC. | $25.02 | 2024 | |
| Noven Therapeutics, LLC | $24.31 | 2025 | Xelstrym |
| Livanova USA, INC. | $22.79 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Sumitomo Pharma America, INC. | $18.02 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Muller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.